Premium
Dendritic cells pulsed with GST–EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma
Author(s) -
Yang BeiBei,
Jiang Hua,
Chen Jia,
Zhang Xing,
Ye JingJia,
Cao Jiang
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21233
Subject(s) - epidermal growth factor receptor , fusion protein , head and neck squamous cell carcinoma , cancer research , ctl* , immunotherapy , medicine , dendritic cell , immunology , immune system , biology , cd8 , receptor , recombinant dna , head and neck cancer , cancer , biochemistry , gene
Background Overexpression of epidermal growth factor receptor (EGFR) is common in head and neck squamous cell carcinoma (HNSCC). Targeting EGFR is an effective approach to treat EGFR‐positive HNSCC. However, the clinical benefits of the present EGFR‐targeting agents are still limited in HNSCC patients. Methods Recombinant glutathione‐S‐transferase (GST)–EGFR fusion protein was produced and purified. Dendritic cells (DCs) of C3H mice were pulsed with fusion protein. Mice were challenged with HNSCC cells before or after vaccination with these DCs, and the cytotoxic T‐lymphocyte (CTL) response, interferon‐γ (IFN‐γ) secretion, tumor growth, and survival of mice were assessed. Results Significant in vitro and in vivo antitumor activities were observed for mice immunized with DCs pulsed with GST–EGFR fusion protein, compared with the control groups ( p < .05). Conclusion The DCs pulsed with GST–EGFR fusion protein can provide not only preventive but also therapeutic antitumor activities against HNSCC in the animal model. © 2009 Wiley Periodicals, Inc. Head Neck, 2010